144 related articles for article (PubMed ID: 24347779)
1. A rare case of imatinib-induced erythroderma.
Verma R; Vasudevan B; Pragasam V; Neema S
Indian J Pharmacol; 2013; 45(6):634-5. PubMed ID: 24347779
[TBL] [Abstract][Full Text] [Related]
2. Imatinib Mesylate Induced Erythroderma.
Lunge S; Bhise R
J Assoc Physicians India; 2018 Dec; 66(12):79-80. PubMed ID: 31313559
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate induced erythroderma.
Sanghavi SA; Dongre AM; Khopkar US
Indian J Dermatol Venereol Leprol; 2012; 78(3):408. PubMed ID: 22565463
[No Abstract] [Full Text] [Related]
4. Erythroderma: An unusual manifestation of imatinib - A rare case report.
Kataria P; Patel A; Kendre P; Tahiliani N; Mule T; Bohra M
J Cancer Res Ther; 2022; 18(1):253-256. PubMed ID: 35381793
[TBL] [Abstract][Full Text] [Related]
5. Imatinib-induced erythroderma.
Mathew T; Chandrashekar L; Pulimood S; Srivastava A
Australas J Dermatol; 2007 Aug; 48(3):193-4. PubMed ID: 17680975
[No Abstract] [Full Text] [Related]
6. Imatinib mesylate induced erythroderma: A rare case series.
Kumar S; Mahajan BB; Kaur S; Banipal RP; Singh A
J Cancer Res Ther; 2015; 11(4):993-6. PubMed ID: 26881566
[TBL] [Abstract][Full Text] [Related]
7. Imatinib-induced Stevens-Johnsons syndrome.
Jha P; Himanshu D; Jain N; Singh AK
BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23349042
[TBL] [Abstract][Full Text] [Related]
8. Imatinib-induced erythroderma mediated by an unusual non-dose-dependent mechanism.
Vano-Galvan S; Fernandez-Guarino M; Henriquez-Santana A; De Las Heras E; Calbacho M; Jaen P
Eur J Dermatol; 2007; 17(6):538-9. PubMed ID: 17951138
[No Abstract] [Full Text] [Related]
9. Successful progressive challenge after a cutaneous reaction to imatinib mesylate (Gleevec): a case report and review of the literature.
Park MA; Volcheck GW; Guarderas JC
Allergy Asthma Proc; 2004; 25(5):345-7. PubMed ID: 15603208
[TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate-induced pseudoporphyria in two children.
Mahon C; Purvis D; Laughton S; Bradbeer P; Teague L
Pediatr Dermatol; 2014; 31(5):603-7. PubMed ID: 24920470
[TBL] [Abstract][Full Text] [Related]
11. Late onset imatinib-induced Stevens-Johnson syndrome.
Bois E; Holle LM; Farooq U
J Oncol Pharm Pract; 2014 Dec; 20(6):476-8. PubMed ID: 24399835
[TBL] [Abstract][Full Text] [Related]
12. Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia.
Machaczka M; Gossart M
Pol Arch Med Wewn; 2013; 123(5):251-2. PubMed ID: 23722191
[No Abstract] [Full Text] [Related]
13. Imatinib (STI-571)-induced exfoliative dermatitis in a Saudi patient with deck chair sign.
Banka N; Aljurf M; Hamadah I
Dermatology; 2003; 207(3):329-30. PubMed ID: 14571082
[No Abstract] [Full Text] [Related]
14. Pityriasis rubra pilaris-like reaction induced by imatinib.
Plana A; Carrascosa JM; Vilavella M; Ferrandiz C
Clin Exp Dermatol; 2013 Jul; 38(5):520-2. PubMed ID: 23777493
[TBL] [Abstract][Full Text] [Related]
15. Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia.
Oztas P; Erbasi S; Lenk N; Polat M; Han O; Artuz F; Alli N
Acta Derm Venereol; 2006; 86(2):174-5. PubMed ID: 16648930
[No Abstract] [Full Text] [Related]
16. Trachyonychia in a patient with chronic myeloid leukaemia after imatinib mesylate.
Lau YM; Lam YK; Leung KH; Lin SY
Hong Kong Med J; 2014 Oct; 20(5):464.e2. PubMed ID: 25307080
[No Abstract] [Full Text] [Related]
17. Indications for imatinib mesylate therapy and clinical management.
Guilhot F
Oncologist; 2004; 9(3):271-81. PubMed ID: 15169982
[TBL] [Abstract][Full Text] [Related]
18. Skin and oral lesions associated to imatinib mesylate therapy.
Basso FG; Boer CC; Corrêa ME; Torrezan M; Cintra ML; de Magalhães MH; da Silva Santos P; de Souza CA
Support Care Cancer; 2009 Apr; 17(4):465-8. PubMed ID: 19037666
[TBL] [Abstract][Full Text] [Related]
19. Imatinib-induced aplastic anemia in a patient with chronic myeloid leukemia.
Mabed M; Elhefni AM; Damnhouri G
Leuk Lymphoma; 2012 Nov; 53(11):2310-1. PubMed ID: 22462614
[No Abstract] [Full Text] [Related]
20. [A patient with acute Philadelphia-chromosome-positive mixed phenotype leukemia developing ecthyma gangrenosum while undergoing combined imatinib mesylate chemotherapy].
Suzuki K; Sekine T
Kansenshogaku Zasshi; 2014 May; 88(3 Suppl 9-10):33-6. PubMed ID: 24979952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
